Loading clinical trials...

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease | Clinical Trials | Clareo Health

COMPLETED

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

NCT01521039•Ohio State University Comprehensive Cancer Center

View on ClinicalTrials.gov

Summary

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease (GVHD).

Detailed Description

The purpose of this study is to examine whether the expression levels of a novel class of molecules, called microRNAs, are associated with acute graft-versus-host disease frequency and severity. Acute graft-versus-host disease is a Acute GVHD is a medical condition that can become very serious. It happens when the donor cells attack and damage your tissues after transplant.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who are receiving allogeneic stem cell transplantation at the Ohio State University Blood and Marrow Transplantation program are eligible and will be consented for the study.

Locations (1)

Ohio State University Medical Center

Columbus, Ohio, United States

Key Dates

Start Date

February 20, 2012

Primary Completion Date

December 30, 2024

Completion Date

December 30, 2024

Last Updated

January 20, 2025

Enrollment

259

ACTUAL participants

Conditions

Acute Graft-versus-Host DiseaseAllogeneic Stem Cell Transplant

Interventions

Blood samples

PROCEDURE

A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

NCT07070674

Acute Graft-versus-Host Disease

View study

RECRUITINGPHASE2

MAGIC Ruxolitinib for aGVHD

NCT06936566

Acute Graft-versus-host DiseaseAllogeneic Bone Marrow Transplantation+1 more

View study

ACTIVE_NOT_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

Inclusion Criteria

A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

MAGIC Ruxolitinib for aGVHD

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Donor Neutrophil Subsets to Predict the Risk of aGVHD

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation